Potato protease inhibitors for inhibition of SARS-CoV-2 (Q3988869): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Fixing summary) |
(Changed an Item: Adding English translations) |
||||||||||||||
| Property / summary | |||||||||||||||
Potato enzyme inhibitors for inhibition of SARS-CoV-2; Prevention and therapy of replication and tissue damageThe COVID-19 pandemic caused by the new coronavirus (SARS-CoV-2) requires, with great urgency, innovative approaches to infection prevention and therapy that counteract the severe lung damage. A prophylactic vaccine would be a huge improvement, but it will also be essential to develop a therapy, especially for urgent situations such as at the moment. Inhibition of host enzymes involved in virus cellular infection is a promising alternative strategy for inhibiting virus infection of the host cell and of virus production by the infected cell. For example, effective therapy against AIDS is based on lifelong therapy with multiple inhibitors of HIV-1. SARS-CoV-2 can also be inhibited in vitro with existing individual inhibitors. However, in vivo effectiveness is still very uncertain, and there is a high risk of developing resistance if only 1 inhibitor is used. Moreover, cost-effective production at clinical grade level of existing enzyme inhibitors for a global market of more than 7 billion people with often low incomes is a very big obstacle. Therefore, there are great opportunities for enzyme inhibitors that can be quickly produced in large quantities and that are safe to use. The proteins from the potato can offer a solution here.Avebe has a great expertise in the purification of the available protein fraction in the juice of starch potatoes. Where in the past potato juice including the protein fraction was a waste product that was discharged into the peat colonial channels until the 1970s, these proteins now find a commercial application in foods such as sorbet ice cream, mayonnaise and confectionery. In addition, from a long-term collaboration between UMCG and Avebe, a specific protein fraction from the potato has been successfully applied to patients with severe skin inflammation. Recently, in vitro, known and new potato proteins have inhibitory activity against specific enzymes involved in human diseases such as increased blood pressure, Alzheimer’s, AIDS and osteoporosis. Strongly similar enzymes act as the receptor for SARS-CoV-2 on cells in the respiratory tract and intestine. Potentially have potato protein fractions inhibiting activity on the infection process of SARS-CoV-2 viruses.In this project application, researchers from Avebe and UMCG want to determine whether SARS-CoV-2 attachment and replication, as well as harmful leukocyte enzymes, can be inhibited by combinations of purified proteins from the potato and can serve as potential new drug candidates. This project brings together the unique patented production process of Avebe and the UMCG’s leading expertise in immunology, virology, lung diseases and haematology. This allows us to develop this innovative solution in the North of the Netherlands that is cost effective due to large economy-of-scale benefits. (English) | |||||||||||||||
| Property / summary: Potato enzyme inhibitors for inhibition of SARS-CoV-2; Prevention and therapy of replication and tissue damageThe COVID-19 pandemic caused by the new coronavirus (SARS-CoV-2) requires, with great urgency, innovative approaches to infection prevention and therapy that counteract the severe lung damage. A prophylactic vaccine would be a huge improvement, but it will also be essential to develop a therapy, especially for urgent situations such as at the moment. Inhibition of host enzymes involved in virus cellular infection is a promising alternative strategy for inhibiting virus infection of the host cell and of virus production by the infected cell. For example, effective therapy against AIDS is based on lifelong therapy with multiple inhibitors of HIV-1. SARS-CoV-2 can also be inhibited in vitro with existing individual inhibitors. However, in vivo effectiveness is still very uncertain, and there is a high risk of developing resistance if only 1 inhibitor is used. Moreover, cost-effective production at clinical grade level of existing enzyme inhibitors for a global market of more than 7 billion people with often low incomes is a very big obstacle. Therefore, there are great opportunities for enzyme inhibitors that can be quickly produced in large quantities and that are safe to use. The proteins from the potato can offer a solution here.Avebe has a great expertise in the purification of the available protein fraction in the juice of starch potatoes. Where in the past potato juice including the protein fraction was a waste product that was discharged into the peat colonial channels until the 1970s, these proteins now find a commercial application in foods such as sorbet ice cream, mayonnaise and confectionery. In addition, from a long-term collaboration between UMCG and Avebe, a specific protein fraction from the potato has been successfully applied to patients with severe skin inflammation. Recently, in vitro, known and new potato proteins have inhibitory activity against specific enzymes involved in human diseases such as increased blood pressure, Alzheimer’s, AIDS and osteoporosis. Strongly similar enzymes act as the receptor for SARS-CoV-2 on cells in the respiratory tract and intestine. Potentially have potato protein fractions inhibiting activity on the infection process of SARS-CoV-2 viruses.In this project application, researchers from Avebe and UMCG want to determine whether SARS-CoV-2 attachment and replication, as well as harmful leukocyte enzymes, can be inhibited by combinations of purified proteins from the potato and can serve as potential new drug candidates. This project brings together the unique patented production process of Avebe and the UMCG’s leading expertise in immunology, virology, lung diseases and haematology. This allows us to develop this innovative solution in the North of the Netherlands that is cost effective due to large economy-of-scale benefits. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Potato enzyme inhibitors for inhibition of SARS-CoV-2; Prevention and therapy of replication and tissue damageThe COVID-19 pandemic caused by the new coronavirus (SARS-CoV-2) requires, with great urgency, innovative approaches to infection prevention and therapy that counteract the severe lung damage. A prophylactic vaccine would be a huge improvement, but it will also be essential to develop a therapy, especially for urgent situations such as at the moment. Inhibition of host enzymes involved in virus cellular infection is a promising alternative strategy for inhibiting virus infection of the host cell and of virus production by the infected cell. For example, effective therapy against AIDS is based on lifelong therapy with multiple inhibitors of HIV-1. SARS-CoV-2 can also be inhibited in vitro with existing individual inhibitors. However, in vivo effectiveness is still very uncertain, and there is a high risk of developing resistance if only 1 inhibitor is used. Moreover, cost-effective production at clinical grade level of existing enzyme inhibitors for a global market of more than 7 billion people with often low incomes is a very big obstacle. Therefore, there are great opportunities for enzyme inhibitors that can be quickly produced in large quantities and that are safe to use. The proteins from the potato can offer a solution here.Avebe has a great expertise in the purification of the available protein fraction in the juice of starch potatoes. Where in the past potato juice including the protein fraction was a waste product that was discharged into the peat colonial channels until the 1970s, these proteins now find a commercial application in foods such as sorbet ice cream, mayonnaise and confectionery. In addition, from a long-term collaboration between UMCG and Avebe, a specific protein fraction from the potato has been successfully applied to patients with severe skin inflammation. Recently, in vitro, known and new potato proteins have inhibitory activity against specific enzymes involved in human diseases such as increased blood pressure, Alzheimer’s, AIDS and osteoporosis. Strongly similar enzymes act as the receptor for SARS-CoV-2 on cells in the respiratory tract and intestine. Potentially have potato protein fractions inhibiting activity on the infection process of SARS-CoV-2 viruses.In this project application, researchers from Avebe and UMCG want to determine whether SARS-CoV-2 attachment and replication, as well as harmful leukocyte enzymes, can be inhibited by combinations of purified proteins from the potato and can serve as potential new drug candidates. This project brings together the unique patented production process of Avebe and the UMCG’s leading expertise in immunology, virology, lung diseases and haematology. This allows us to develop this innovative solution in the North of the Netherlands that is cost effective due to large economy-of-scale benefits. (English) / qualifier | |||||||||||||||
point in time: 15 December 2021
| |||||||||||||||
Revision as of 06:20, 15 December 2021
Project Q3988869 in Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Potato protease inhibitors for inhibition of SARS-CoV-2 |
Project Q3988869 in Netherlands |
Statements
305,644.0 Euro
0 references
807,513.871 Euro
0 references
37.85 percent
0 references
1 May 2020
0 references
31 July 2021
0 references
Academisch Ziekenhuis Groningen UMCG
0 references
53°13'8.94"N, 6°33'47.48"E
0 references
9700 RB
0 references
9640 AA
0 references
9712CP
0 references
Enzym-inhibitors uit aardappel voor remming van SARS-CoV-2; Preventie en therapie van replicatie en weefselschadeDe COVID-19 pandemie veroorzaakt door het nieuwe coronavirus (SARS-CoV-2) vraagt met grote urgentie om innovatieve benaderingen voor infectie-preventie en therapie die de ernstige longschade tegengaat. Een profylactisch vaccin zou een enorme verbetering betekenen, maar daarnaast zal het ook essentieel zijn om een therapie te ontwikkelen, zeker voor urgente situaties zoals op dit moment. Remming van gastheer-enzymen die betrokken zijn bij cellulaire infectie door virussen is een veelbelovende alternatieve strategie voor het remmen van virus infectie van de gastheercel en van virus productie door de geïnfecteerde cel. Zo berust effectieve therapie tegen AIDS op levenslange therapie met meerdere inhibitors van HIV-1. Ook SARS-CoV-2 kan in vitro geremd worden met bestaande individuele inhibitors. In vivo effectiviteit is echter nog zeer onzeker, en er bestaat een groot risico op het ontwikkelen van resistentie als slechts 1 inhibitor wordt gebruikt. Bovendien is kosten-effectieve productie op clinical grade niveau van bestaande enzym inhibitors voor een wereldwijde markt van meer dan 7 miljard mensen met veelal lage inkomens een zeer groot obstakel. Daarom zijn er grote kansen voor enzym remmers die snel in grote hoeveelheden kunnen worden geproduceerd en die veilig zijn in gebruik. De eiwitten uit de aardappel kunnen hier een oplossing bieden.Avebe heeft een grote expertise op het terrein van zuivering van de beschikbare eiwitfractie in het sap van zetmeelaardappelen. Waar in het verleden het aardappelsap inclusief de eiwitfractie een afvalproduct was dat tot in de jaren 70 geloosd werd op de veenkoloniale kanalen, vinden deze eiwitten nu een commerciële toepassing in voedingsmiddelen zoals sorbetijs, mayonaise en suikerwaren. Daarnaast is uit een langlopend samenwerkingsverband tussen UMCG en Avebe een specifieke eiwit fractie uit de aardappel succesvol toegepast op patiënten met ernstige huidontsteking. Recent is in vitro aangetoond dat bekende en nieuwe aardappel eiwitten tevens remmende activiteit hebben tegen specifieke enzymen betrokken in humane ziekten zoals verhoogde bloeddruk, Alzheimer’s, AIDS en osteoporose. Sterk vergelijkbare enzymen fungeren als de receptor voor SARS-CoV-2 op cellen in de luchtwegen en de darm. Potentieel bezitten aardappeleiwit fracties remmende activiteit op het infectie proces van SARS-CoV-2 virussen.In deze projectaanvraag willen onderzoekers van Avebe en UMCG vaststellen of SARS-CoV-2 aanhechting en replicatie, zowel als schadelijke leukocyt-enzymen, kunnen worden geremd door combinaties van gezuiverde eiwitten uit de aardappel en kunnen dienen als potentiële nieuwe medicijn kandidaten. Dit project brengt het unieke gepatenteerde productieproces van Avebe en de vooraanstaande expertise van het UMCG op het gebied van immunologie, virologie, longziekten en hematologie samen. Hierdoor kunnen wij in Noord-Nederland deze innovatieve oplossing ontwikkelen die kosten effectief is door grote economy-of-scale voordelen. (Dutch)
0 references
Potato enzyme inhibitors for inhibition of SARS-CoV-2; Prevention and therapy of replication and tissue damageThe COVID-19 pandemic caused by the new coronavirus (SARS-CoV-2) requires, with great urgency, innovative approaches to infection prevention and therapy that counteract the severe lung damage. A prophylactic vaccine would be a huge improvement, but it will also be essential to develop a therapy, especially for urgent situations such as at the moment. Inhibition of host enzymes involved in virus cellular infection is a promising alternative strategy for inhibiting virus infection of the host cell and of virus production by the infected cell. For example, effective therapy against AIDS is based on lifelong therapy with multiple inhibitors of HIV-1. SARS-CoV-2 can also be inhibited in vitro with existing individual inhibitors. However, in vivo effectiveness is still very uncertain, and there is a high risk of developing resistance if only 1 inhibitor is used. Moreover, cost-effective production at clinical grade level of existing enzyme inhibitors for a global market of more than 7 billion people with often low incomes is a very big obstacle. Therefore, there are great opportunities for enzyme inhibitors that can be quickly produced in large quantities and that are safe to use. The proteins from the potato can offer a solution here.Avebe has a great expertise in the purification of the available protein fraction in the juice of starch potatoes. Where in the past potato juice including the protein fraction was a waste product that was discharged into the peat colonial channels until the 1970s, these proteins now find a commercial application in foods such as sorbet ice cream, mayonnaise and confectionery. In addition, from a long-term collaboration between UMCG and Avebe, a specific protein fraction from the potato has been successfully applied to patients with severe skin inflammation. Recently, in vitro, known and new potato proteins have inhibitory activity against specific enzymes involved in human diseases such as increased blood pressure, Alzheimer’s, AIDS and osteoporosis. Strongly similar enzymes act as the receptor for SARS-CoV-2 on cells in the respiratory tract and intestine. Potentially have potato protein fractions inhibiting activity on the infection process of SARS-CoV-2 viruses.In this project application, researchers from Avebe and UMCG want to determine whether SARS-CoV-2 attachment and replication, as well as harmful leukocyte enzymes, can be inhibited by combinations of purified proteins from the potato and can serve as potential new drug candidates. This project brings together the unique patented production process of Avebe and the UMCG’s leading expertise in immunology, virology, lung diseases and haematology. This allows us to develop this innovative solution in the North of the Netherlands that is cost effective due to large economy-of-scale benefits. (English)
15 December 2021
0 references
Identifiers
OP-2014-2023-Noord-OPSNN0312
0 references